attr cardiac amyloidosis - Health Topics
Novel directed therapies for transthyretin cardiac amyloidosis (ATTR) have been shown to improve outcomes and reduce the long-term negative effects of unchecked amyloid proliferation in patients with ... Cardiac transthyretin amyloidosis (also called ATTR amyloidosis cardiomyopathy or ATTR-CM) is a progressive disease and a cause of fatal heart failure resulting from extracellular myocardial ... With targeted treatment using both medical therapy for transthyretin-associated cardiac amyloidosis (ATTR-CA) and valve replacement for aortic stenosis (AS), patients with the dual pathology can fare ...
Understanding the Context
Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure (HF) in older Black individuals, particularly in the oldest men, the prospective SCAN-MP study affirms. The highest ... The New England Journal of Medicine: Antibody-Associated Reversal of ATTR Amyloidosis–Related Cardiomyopathy "ATTR amyloidosis was characterized by distinct patterns of functional impairment across all disease phenotypes, attributable to multiple physiological mechanisms. Multiple CPET parameters were ...
Image Gallery
Key Insights
EurekAlert!: New PET model for quantifying cardiac amyloidosis allows for more accurate diagnosis and monitoring New PET model for quantifying cardiac amyloidosis allows for more accurate diagnosis and monitoring Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment. Cardiac ... Healio: Common ATTR amyloidosis gene could impair longevity among many Black carriers Please provide your email address to receive an email when new articles are posted on . Roughly 3% of the Black U.S. population are carriers of an ATTR amyloidosis-causing gene.
Related Articles You Might Like:
range of normal blood glucose necrotising fasciitis images benefits of probiotic drinksFinal Thoughts
Among all carriers ... TCTMD: Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients MarketWatch: Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ... Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG Berkshire Eagle: Cardiac amyloidosis is a rare but treatable heart condition. Here's what to know Cardiac amyloidosis is a rare but treatable heart condition. Here's what to know